Global Next-Generation Sequencing (NGS) Sample Prep Kits Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Global Next-Generation Sequencing (NGS) Sample Prep Kits Market Segmentation, By Product Type (Whole Genome Sequencing Kits, Targeted Sequencing Kits, RNA Sequencing Kits, Exome Sequencing Kits, and Others), By Application (Oncology, Reproductive Health, Infectious Disease, Agrigenomics & Forensics, and Others), By End User (Academic & Research Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others) - Industry Trends and Forecast to 2033

Next-Generation Sequencing (NGS) Sample Prep Kits Market Size

• The global Next-Generation Sequencing (NGS) Sample Prep Kits market size was valued at USD 2.14 billion in 2025 and is expected to reach USD 6.87 billion by 2033, at a CAGR of 15.70% during the forecast period
• The market growth is largely fueled by the rapid advancements in sequencing technologies and increasing adoption of precision medicine approaches, along with rising investments in genomics research and personalized therapy development, leading to expanded applications of NGS sample prep kits in disease diagnostics and biomarker discovery
• In addition, growing prevalence of cancer, infectious diseases, and rare genetic disorders, coupled with strong clinical pipeline activity and increasing focus on genomic medicine, is establishing NGS sample prep kits as an essential component of next-generation diagnostic workflows. These converging factors are accelerating the uptake of NGS Sample Prep Kits solutions, thereby significantly boosting the market growth

Next-Generation Sequencing (NGS) Sample Prep Kits Market Analysis

• NGS sample prep kits, designed to process and prepare biological specimens for high-throughput sequencing by fragmenting, enriching, and ligating adapters to nucleic acid samples, are emerging as a foundational component in modern genomics due to their precision, scalability, and broad applicability across multiple research and clinical areas
• The escalating demand for NGS sample prep kits is primarily fueled by increasing prevalence of cancer, infectious diseases, and rare genetic disorders, along with strong advancements in library preparation technologies, sequencing platform innovation, and growing investments in genomics and biotechnology research
• North America dominated the NGS sample prep kits market with the largest revenue share of approximately 43.5% in 2025, characterized by strong genomics infrastructure, high R&D investment, and early adoption of next-generation sequencing platforms, with the U.S. leading in clinical trials and commercialization efforts
• Asia-Pacific is expected to be the fastest growing region in the NGS sample prep kits market during the forecast period due to expanding biotechnology sector, increasing government funding, and rising focus on advanced genomics and diagnostics development
• The Oncology segment dominated the largest market revenue share of 36.8% in 2025, driven by the rising global cancer burden and rapid adoption of personalized medicine approaches

Report Scope and Next-Generation Sequencing (NGS) Sample Prep Kits Market Segmentation

Next-Generation Sequencing (NGS) Sample Prep Kits Market Trends

“Advancements in Library Preparation Technologies and Next-Generation Diagnostic Development”

• A significant and accelerating trend in the global NGS Sample Prep Kits market is the increasing adoption of advanced library preparation technologies for the development of next-generation sequencing-based diagnostics and targeted therapies. These innovations are transforming the diagnostic landscape for oncology, infectious diseases, and rare genetic disorders
• For instance, NGS sample prep platforms enable the rapid design and preparation of sequencing libraries by enriching specific genomic regions that can facilitate disease detection or genetic profiling
• Continuous improvements in low-input library preparation protocols are significantly enhancing the sensitivity and reproducibility of NGS-based assays
• In addition, advancements in automation and microfluidics-based workflows are improving throughput and reducing hands-on preparation time, thereby increasing laboratory efficiency
• Growing investment in personalized medicine approaches is also accelerating the development of patient-specific genomic profiling solutions
• This trend toward highly adaptable, fast-developing, and precision-based diagnostic platforms is significantly shaping the global NGS Sample Prep Kits market

Next-Generation Sequencing (NGS) Sample Prep Kits Market Dynamics

Driver

“Rising Prevalence of Chronic Diseases and Expanding Applications of NGS Technology”

• The increasing global burden of chronic diseases such as cancer, infectious diseases, and rare genetic disorders is a major driver of the NGS Sample Prep Kits market
• For instance, the success of NGS-based diagnostics during global health emergencies has significantly accelerated research and development in clinical genomics applications beyond infectious disease identification
• Growing demand for targeted and personalized treatment approaches is encouraging pharmaceutical companies to invest heavily in NGS-based genomic profiling solutions
• Expanding clinical trials exploring NGS-driven diagnostics for oncology, reproductive health, and metabolic disorders are further supporting market growth
• Increasing government funding and supportive regulatory frameworks for advanced genomic diagnostics are also contributing to market expansion
• Rapid technological advancements in biotechnology and molecular diagnostics are enabling faster commercialization of novel NGS-based sample preparation solutions globally

Restraint/Challenge

“Complex Workflow Requirements and Stringent Regulatory Requirements”

• The complex library preparation workflows and quality control requirements of NGS sample prep kits remain a significant challenge for large-scale clinical implementation
• These kits require highly skilled personnel, controlled laboratory environments, and sophisticated bioinformatics capabilities to ensure data accuracy and reproducibility
• For instance, maintaining nucleic acid integrity during extraction, fragmentation, and adapter ligation continues to be a major technical limitation for routine clinical workflows
• In addition, stringent regulatory approval processes for novel in vitro diagnostic kits can delay product development timelines and increase overall costs
• High research and development expenses associated with assay validation and manufacturing scale-up further restrict market entry for smaller companies
• Addressing these challenges through improved automation, standardized preparation protocols, and streamlined regulatory pathways will be essential for sustained growth of the NGS Sample Prep Kits market

Next-Generation Sequencing (NGS) Sample Prep Kits Market Scope

The market is segmented on the basis of product type, application, and end user.

• By Product Type

On the basis of product type, the NGS Sample Prep Kits market is segmented into Whole Genome Sequencing Kits, Targeted Sequencing Kits, RNA Sequencing Kits, Exome Sequencing Kits, and Others. The Whole Genome Sequencing Kits segment dominated the largest market revenue share of 34.5% in 2025, driven by the increasing demand for comprehensive genomic profiling across oncology, rare diseases, and population genomics studies. These kits provide complete genetic information, enabling high-resolution analysis of mutations and structural variations. Expanding adoption in large-scale research initiatives and national genome programs is further strengthening demand. Pharmaceutical and biotechnology companies are increasingly relying on whole genome data to support drug discovery pipelines. Continuous improvements in sequencing accuracy and reduced per-sample cost are enhancing accessibility. Growing integration with AI-based genomic interpretation tools is improving clinical utility. Academic research institutions are major contributors to high-volume usage. Rising demand for precision medicine is also accelerating uptake. North America and Europe remain key revenue-generating regions due to strong genomic infrastructure. Overall, this segment remains the backbone of comprehensive NGS workflows globally.

The Targeted Sequencing Kits segment is expected to witness the fastest CAGR of 17.4% from 2026 to 2033, driven by increasing demand for cost-effective, high-throughput, and clinically actionable genomic testing. These kits enable focused analysis of specific genes or regions, making them highly suitable for oncology panels and inherited disease testing. Growing adoption in clinical diagnostics is boosting routine use in hospitals and laboratories. Faster turnaround time compared to whole genome sequencing is a major advantage supporting uptake. Rising demand for companion diagnostics in personalized medicine is significantly driving growth. Pharmaceutical companies are increasingly using targeted panels in clinical trials for biomarker validation. Expanding applications in liquid biopsy testing are further strengthening demand. Continuous improvements in multiplexing capability are increasing efficiency. Emerging economies are rapidly adopting targeted sequencing due to lower cost barriers. Increasing reimbursement support for panel-based testing is also contributing to market expansion. Overall, this segment is growing rapidly due to its balance of affordability, speed, and clinical relevance.

• By Application

On the basis of application, the NGS Sample Prep Kits market is segmented into Oncology, Reproductive Health, Infectious Disease, Agrigenomics & Forensics, and Others. The Oncology segment dominated the largest market revenue share of 36.8% in 2025, driven by the rising global cancer burden and rapid adoption of personalized medicine approaches. Increasing use of NGS-based tumor profiling and liquid biopsy approaches is supporting strong clinical uptake due to their ability to detect actionable mutations and guide targeted therapies. Pharmaceutical companies are heavily investing in oncology-focused genomics pipelines, which is accelerating innovation. Expanding clinical trials and favorable regulatory pathways are further strengthening segment growth. The availability of advanced low-input library preparation kits is improving sensitivity and effectiveness for rare mutation detection. Growing collaboration between biotech firms and research institutes is accelerating development timelines. Rising healthcare expenditure and unmet oncology diagnostic needs are also major contributors. North America continues to dominate due to strong R&D infrastructure, while Europe is steadily expanding clinical adoption. Continuous pipeline expansion is improving long-term commercial potential. Overall, oncology remains the most lucrative application area for NGS sample prep kits.

The Infectious Disease segment is expected to witness the fastest CAGR of 16.9% from 2026 to 2033, driven by increasing demand for rapid pathogen identification and surveillance platforms. The success of NGS-based diagnostics during global pandemics has significantly boosted confidence in this technology. Governments worldwide are investing in pandemic preparedness programs, further accelerating adoption. NGS platforms allow faster and more comprehensive pathogen characterization compared to traditional diagnostic technologies. Rising prevalence of emerging infectious diseases is increasing demand for flexible and scalable sequencing solutions. Pharmaceutical companies are expanding manufacturing capacity to meet future outbreak requirements. Continuous advancements in metagenomic sequencing are improving pathogen detection efficiency. Strong pipeline development for influenza, RSV, and other emerging viral infections is supporting growth. Regulatory agencies are also streamlining approval processes for emergency diagnostic kits. Public health initiatives and awareness campaigns are improving testing coverage. Emerging economies are increasingly adopting modern molecular diagnostic platforms. Overall, this segment is expanding rapidly due to global health security priorities.

• By End User

On the basis of end user, the NGS Sample Prep Kits market is segmented into Academic & Research Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others. The Pharmaceutical & Biotechnology Companies segment dominated the largest market revenue share of 51.3% in 2025, driven by strong R&D investments and large-scale drug development programs. These companies are the primary innovators in genomics-based drug discovery and lead most clinical sequencing programs globally. Significant funding availability allows them to invest in advanced library preparation systems and scalable production technologies. Strategic collaborations, licensing deals, and mergers are further strengthening market dominance. Companies are increasingly focusing on oncology, infectious diseases, and rare genetic disorders. Integration of AI and bioinformatics tools is accelerating genomic data analysis processes. Established regulatory expertise helps in faster approvals and commercialization. North America remains the leading region due to strong biotech presence. Continuous expansion of genomics pipelines is enhancing growth prospects. High production capabilities enable large-scale sequencing and diagnostic kit manufacturing. Overall, this segment remains the backbone of NGS sample prep kit innovation.

The Academic & Research Institutes segment is expected to witness the fastest CAGR of 15.8% from 2026 to 2033, driven by increasing public and private funding for molecular and genomic research. Academic and clinical research collaborations are expanding rapidly across global institutions. These institutes play a crucial role in early-stage discovery and validation of NGS-based assays. Rising focus on precision medicine and genetic research is boosting demand for advanced sequencing tools and platforms. Government grants and international funding programs are accelerating innovation. Increasing participation in global research consortiums is strengthening knowledge sharing. Technological advancements in sequencing and molecular biology are enhancing research outcomes. Growing emphasis on translational research is bridging the gap between laboratory discoveries and clinical applications. Asia-Pacific is emerging as a fast-growing hub for academic research expansion. Strong infrastructure development in universities and sequencing facilities is supporting growth. Overall, this segment is gaining momentum due to rising scientific collaboration and funding support.

Next-Generation Sequencing (NGS) Sample Prep Kits Market Regional Analysis

• North America dominated the next-generation sequencing (NGS) sample prep kits market  with the largest revenue share of approximately 43.5% in 2025, characterized by strong genomics infrastructure, high R&D investment, and early adoption of next-generation sequencing platforms
• The region benefits from a robust ecosystem of biotech companies, leading research institutions, and favorable regulatory pathways supporting rapid clinical development and commercialization of NGS-based diagnostic and research kits. The U.S. leads in clinical trials, innovation, and large-scale genomic pipeline development
• Increasing prevalence of chronic and infectious diseases, rising demand for personalized genomics, and growing investments in advanced molecular and genetic diagnostics are key factors driving market growth in North America. Continuous advancements in library preparation technologies and strong funding from both public and private sectors further support market expansion

U.S. NGS Sample Prep Kits Market Insight

The U.S. next-generation sequencing (NGS) sample prep kits market  captured the largest revenue share within North America in 2025, driven by its leadership in genomics innovation and strong clinical research activity. The country has a well-established ecosystem of pharmaceutical and biotech companies actively developing NGS-based diagnostic and research kits. High R&D funding, strong academic-industry collaboration, and rapid regulatory approvals are accelerating market growth.

Europe NGS Sample Prep Kits Market Insight

The Europe next-generation sequencing (NGS) sample prep kits market  is projected to expand at a substantial CAGR during the forecast period, supported by increasing investments in genomics research and strong government backing for advanced diagnostic development. The region is witnessing growing collaboration between academic institutions and biotech firms, particularly in Germany, France, and the U.K., which is accelerating innovation in NGS library preparation platforms.

U.K. NGS Sample Prep Kits Market Insight

The U.K. next-generation sequencing (NGS) sample prep kits market  is expected to grow at a notable CAGR, driven by strong biomedical research infrastructure and increasing funding for genomic medicine. The presence of leading research universities and biotech startups is fostering innovation in NGS-based kit development. In addition, national healthcare initiatives supporting advanced genomic diagnostics are contributing to market expansion.

Germany NGS Sample Prep Kits Market Insight

The Germany next-generation sequencing (NGS) sample prep kits market  is anticipated to expand at a considerable CAGR, fueled by strong pharmaceutical manufacturing capabilities and a well-established biotechnology sector. Germany is a key hub for NGS research and production, supported by substantial investments in life sciences and a strong focus on translational genomics research.

Asia-Pacific NGS Sample Prep Kits Market Insight

The Asia-Pacific next-generation sequencing (NGS) sample prep kits market  is expected to grow at the fastest CAGR during the forecast period, driven by expanding genomics capabilities, increasing government funding, and rising focus on advanced diagnostics development. Countries such as China, Japan, and South Korea are investing heavily in NGS research infrastructure and clinical development programs, accelerating regional growth.

Japan NGS Sample Prep Kits Market Insight

The Japan next-generation sequencing (NGS) sample prep kits market  is gaining momentum due to strong government support for regenerative medicine and advanced genomics. The country's aging population and high healthcare standards are driving demand for innovative diagnostic solutions. Japan's biotechnology firms are increasingly investing in NGS technology for precision medicine and population genomics applications.

China NGS Sample Prep Kits Market Insight

The China next-generation sequencing (NGS) sample prep kits market  accounted for the largest revenue share in Asia-Pacific in 2025, supported by rapid expansion of the domestic biotechnology sector and increasing investment in advanced genomics development. Strong government initiatives, rising clinical research activity, and growing collaborations with global biotech firms are key factors driving market growth.

Next-Generation Sequencing (NGS) Sample Prep Kits Market Share

The Next-Generation Sequencing (NGS) Sample Prep Kits industry is primarily led by well-established companies, including:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• Agilent Technologies, Inc. (U.S.)
• Pacific Biosciences of California, Inc. (U.S.)
• Oxford Nanopore Technologies plc (U.K.)
• 10x Genomics, Inc. (U.S.)
• Roche Holding AG (Switzerland)
• Bio-Rad Laboratories, Inc. (U.S.)
• Becton, Dickinson and Company (U.S.)
• New England Biolabs (U.S.)
• Takara Bio Inc. (Japan)
• Twist Bioscience Corporation (U.S.)
• Genapsys Inc. (U.S.)
• MGI Tech Co., Ltd. (China)
• Nucleics (Australia)
• PerkinElmer Inc. (U.S.)
• Zymo Research Corporation (U.S.)
• Swift Biosciences (U.S.)
• Integrated DNA Technologies (U.S.)

Latest Developments in Global Next-Generation Sequencing (NGS) Sample Prep Kits Market

• In November 2021, Illumina launched the DRAGEN Enrichment pipeline update, enabling significantly faster and more accurate variant calling from targeted NGS library preparations, marking a major advancement in integrated sample prep and bioinformatics workflows for clinical genomics
• In August 2022, QIAGEN expanded its QIAseq NGS portfolio with new targeted enrichment panels and compatible library preparation kits optimized for low-input clinical samples, representing a major advancement in flexible and sensitive sample preparation for oncology and rare disease diagnostics
• In February 2023, Thermo Fisher Scientific broadened its Ion Torrent NGS library preparation portfolio through global clinical collaborations, including large-scale validation of its Oncomine Precision Assay kits targeting solid tumor mutation profiling across multiple healthcare systems
• In April 2024, MGI Tech received regulatory clearance in multiple markets to commercialize its DNBSEQ-based library preparation kits (MGIEasy series), marking one of the first major expansions of Chinese NGS sample prep platforms into international clinical diagnostics markets
• In September 2024, Agilent Technologies advanced its SureSelect XT HS2 hybrid capture library preparation kit into broader clinical validation studies after demonstrating superior on-target rates and uniformity across diverse sample types, reinforcing investment in next-generation NGS enrichment kits
• In November 2024, Oxford Nanopore Technologies strengthened its NGS sample prep kit portfolio by acquiring library preparation chemistry assets compatible with its long-read sequencing platforms, supporting expansion into structural variant detection and epigenomics applications
• In March 2025, Illumina received U.S. FDA clearance for its TruSight Oncology 500 ctDNA assay paired library preparation kit (TSO500 ctDNA), a next-generation NGS sample prep solution demonstrating superior sensitivity and expanded platform capability for liquid biopsy-based cancer monitoring

SKU-75686